Cost-effectiveness analysis of zhibituo and simvastatin in treatment of hyperlipemia
- VernacularTitle:脂必妥与辛伐他汀调节血脂代谢的成本-效果分析
- Author:
Jinping ZHANG
- Publication Type:Journal Article
- Keywords:
Hyperlipemias;
Zhibituo;
Simvastation;
Ecomomics,pharmaceutical
- From:
Chinese Journal of Primary Medicine and Pharmacy
2008;15(4):590-591
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the cost-effectiveness analysis of zhibituo and simvastatin in treatment of hyperlipemia. Methods 68 cases with hyperlipemia were divided into two groups randomly:group A were treated with imvastatin (n = 33),group B were treated with zhibituo(n = 35). The data was evaluated with eost-effectiveneas analysis. Results The cost of the two groups was 462.56 yuan and 257.60 yuan respectivdy. The effective rate was 74.28 % and 73.9.3 %respectivdy. The cost-effectiveness ratio was 6.23 and 3.48 respectively. The increased cost-effectiveness ratio of group A vs group B was 585.6. No significant differences were found in both effective rate and ADRS between two groups(P＞0.05).Conclusion Zhibituo was an effective and safe drug in treating hyperlipidemia as well as simvastatin. But zhibituo was better than simvastatin based on the oost-effeetiveness analysis.
